Johnson & Johnson (NYSE:JNJ) Rating Reiterated by Cantor Fitzgerald

Johnson & Johnson (NYSE:JNJ)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a research note issued on Thursday, Benzinga reports. They presently have a $215.00 price objective on the stock. Cantor Fitzgerald’s price target suggests a potential upside of 44.55% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Morgan Stanley decreased their price objective on Johnson & Johnson from $168.00 to $167.00 and set an “equal weight” rating for the company in a report on Wednesday, April 17th. Bank of America lowered their price target on Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, April 17th. StockNews.com lowered Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research report on Monday, June 10th. HSBC raised Johnson & Johnson from a “hold” rating to a “buy” rating and lifted their price target for the stock from $169.00 to $170.00 in a research report on Thursday, April 18th. Finally, The Goldman Sachs Group began coverage on Johnson & Johnson in a research report on Thursday, May 30th. They issued a “neutral” rating and a $160.00 price target for the company. Eight research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Hold” and a consensus target price of $174.07.

Johnson & Johnson Price Performance

JNJ opened at $148.74 on Thursday. The stock has a fifty day simple moving average of $148.05 and a two-hundred day simple moving average of $154.38. The company has a current ratio of 1.17, a quick ratio of 0.94 and a debt-to-equity ratio of 0.36. The company has a market cap of $357.97 billion, a price-to-earnings ratio of 9.27, a price-to-earnings-growth ratio of 2.42 and a beta of 0.53. Johnson & Johnson has a 12-month low of $143.13 and a 12-month high of $175.97.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, April 16th. The company reported $2.71 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.64 by $0.07. The business had revenue of $21.38 billion during the quarter, compared to the consensus estimate of $21.39 billion. Johnson & Johnson had a return on equity of 36.70% and a net margin of 45.26%. The firm’s quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $2.68 earnings per share. Research analysts predict that Johnson & Johnson will post 10.63 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Johnson & Johnson

A number of large investors have recently made changes to their positions in JNJ. Christopher J. Hasenberg Inc purchased a new position in shares of Johnson & Johnson during the 1st quarter valued at about $31,000. Keener Financial Planning LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at about $40,000. WFA Asset Management Corp lifted its position in shares of Johnson & Johnson by 61.4% during the 4th quarter. WFA Asset Management Corp now owns 255 shares of the company’s stock valued at $40,000 after buying an additional 97 shares in the last quarter. Vermillion & White Wealth Management Group LLC purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at about $44,000. Finally, Disciplined Equity Management Inc. purchased a new position in shares of Johnson & Johnson during the 4th quarter valued at about $45,000. 69.55% of the stock is currently owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.